Opko Health, Frost Group, SuperArray Bioscience, Carnegie Institution

Dec 06, 2007

Premium

Opko to Sell $20M in Stock to Frost Group

Opko Health said this week that it has sold $20 million in stock to the Frost Group, a private investment firm run by Opko Chairman and CEO Phillip Frost.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Dual Listings Sought

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

Allocating the Grant Pie

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

More Proposed for NSF

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

This Week in PNAS

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Featured White Papers

What to Look for in an Informatics Platform for Biologics R&D

The Ultimate Guide to Mouse Clinical Trials

Highly Resolved Separation of DNA Fragments on the Fragment Analyzer

How to Perform Successful CRISPR Experiments

Jul

19

Featured Webinar

Advances in NGS for Ultra-High Sensitivity Applications in Translational and Clinical Research

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.

Main menu